BATON ROUGE Critics all over the country ask why drug Dsuvia is needed. It's a new opioid and analgesic drug recently approved by the FDA, but many people are disobedient and think it's a terrible mistake.
"We are probably in the middle of the worst epidemic that is the opioid epidemic in the country, which will probably kill and hurt more than any other epidemic than the country or the world has seen," said Coroner Beau Clark.
East Baton Rouge Parish Coroner, Dr.Beau Clark, has first and foremost considered the lethal effects of opioid use with at least 72 overdose deaths in the congregation alone this year.
"This seems like a real imbalance to human life. We are talking about a subject, Opioids that kill people, why do we need more when we have a problem with what we have," says Clark.
According to the FDA, there are strict guidelines for the drug that dissolves in the mouth. It can only be used in hospitals, surgical centers and emergency rooms. Dsuvia should not be used for more than 72 hours, and it is not available in retail pharmacies.
They say that this is a drug that will only be administered at a healthcare facility for a very short time in a highly controlled environment. It's good if that's the case. But later in the statement, they say that this was also developed with the Department of Defense, so it is also opposed.
In a statement from the FDA Commission, Dr. Scott Gottlieb says: "This opioid formulation, along with Dsuvia's unique delivery device, was a media priority product for the Pentagon because it fills a specific and important but unresolved need to treat our nation's soldiers on battlefields, but Dr. Clark buys not that.
"A soldier is out there to protect our country and if they get injured on the battlefield, we must have mechanisms to cope with their pain especially if they have a long journey from where they get injured and final care but I think they already exist, Says Clark.
Serious risks of using Dsuvia include respiratory depression, coma and even death and not to mention the high addictive quality.
"Having stronger and stronger opioids is really the wrong direction and really sends the error message." In Dr Gottlieb's statement about Dsuvia, he added: "We will not postpone what I think is the true underlying source of dissatisfaction among the critics of this approval, the question of whether America needs another powerful opioid in a massive abuse crisis."
Gottlieb says that the issue will be addressed openly and directly. Dsuvia will raise $ 1.1 billion in annual sales, but for Clark, he is more concerned about the lives that can get lost in the future.
"We are heading for another record year to increase the opioid compared to last year, and I do not see an end in sight, and when we do something like that, and we create another category of an even more powerful opioid I think that leads to more and more problems, says Clark.
For more information about Dsuvia, click here.